11βHSD-1/2 1927
11p15.5 2216
17β-hydroxysteroid dehydrogenase 547
18F-FDG PET/CT 1046
1p 1553
5-aza-2′-deoxycytidine 2024
5-fluorouracil 24, 259, 634, 722, 832, 1644, 2122
5-FU 1850
80 kDa fragment 2018
acitretin 696
activation signaling 305
acute renal failure 480
acute-phase protein response 673
ADCC 342
adenoma 736
adenovirus 882
adhesion 729
adjuvant 24, 843
adjuvant chemotherapy 259, 2107
adjuvant radiochemotherapy 1051
adjuvant therapy 467, 1655
adrenal incidentalomas 1104
advanced biliary cancer 1650
advanced breast cancer 639
advanced gastric cancer 246, 1644
advanced ovarian cancer 1019
Africa 1808
age 949, 955
age at births 167
AIDS 194
Akt 1711
alcohol 426
alcohol dehydrogenase 2039
alcohol drinking 182
allelic imbalance 2181
AlPcS2a 2004
anal cancer 1221
anaplastic thyroid cancer 1899, 2216
androgen receptor 140
aneuploidy 1759
angiogenesis 89, 94, 1182, 1493, 1696, 1720, 1955
angiotensin 1247
anthracyclines 467, 475, 639
antiangiogenic 1599
antibiotics 594
antibody 1430
antihypertensives 1302
anti-idiotypic antibodies 1358
antineoplasic drugs 690
antisense 532
antivascular 1599
anxiety 990, 1393
apoptosis 120, 328, 359, 513, 681, 705, 736, 1089, 1188, 1247, 1430, 1467, 1593, 1773, 1955, 2185, 2225
Arg72Pro mutation 1144
array CGH 1553
arthroplasty 1298
asbestos 580
ascites and metastasis 1475
ascitic fluid 895
Ashkenazi Jewish melanoma families 2278
AT1 1247
atomic force microscopy 1499
audit 55
autologous stem cell transplantation 1984
β1 integrin 1499
β3-integrin expression 41
β-catenin 1581
Barrett’s metaplasia 888
basic fibroblast growth factor 705
BAY 43-9006 1855
Bcl-2 family 449
benzo[b]thiophenesulphonamides 690
Bid 1459
BimEL 1773
bioconjugation 1442
biological marker 1231
biomarker 236, 1599
biotin 1261
birth interval 167
bisphosphonates 1869
bladder 125
bladder cancer 625, 645, 1276, 1906, 2145, 2153, 2262
bladder transitional cell carcinoma 80
BNP7787 1636
body composition 673
body shape 2042
bone marrow 503
bone pain 1869
bowel function 1209
BRAF 2032
brain metastases 815
BRCA in men 1288
BRCA1 857
breast 60, 613, 618, 949, 955
breast cancer 47, 55, 147, 167, 201, 225, 231, 342, 382, 467, 547, 553, 594, 597, 634, 906, 1013, 1283, 1293, 1366, 1524, 1531, 1614, 1621, 1720, 1869, 1922, 1948, 1955, 2039, 2049, 2102, 2206
breast cancer survival 961
breast carcinoma 120, 156, 631, 1261
breast neoplasms 2042
breast neoplasms/pathology 2201
breast tumours 389
breast volume 857
BRG1 1126
cachexia 1830
cadherin superfamily 2010
cadherin-16 2010
cancer 334, 1862, 2097, 2166, 2148
cancer cachexia 876
cancer genetics 1671
cancer incidence 201
cancer invasion 252
cancer mortality 580, 1329
cancer networks 1201
cancer prevention 971
cancer registries 188, 576, 1288
Cancer Research UK 1830
cancer risk 182, 572
cancer screening 265
cancer survival 1808
cancer therapy 1599
cancer vaccines 1358, 1421
capecitabine 246, 820, 2129
carboxylesterase 882
carboxypeptidase G2 480
carcinogenesis 562, 888
carcinoma 15, 736
carcinoma in situ 1934
case–control studies, 594, 607, 1614, 1794, 2065, 2102
case-mix adjustment 55
CBS 838
CCL2 2024
CD1a 888
CD44 1767
CD4+ and CD8+ T-lymphocytes 651
CD4+ T-cell subsets 913
CD4+CD25+ T cells 913
CDC 342
CDK4 2278
CDKN2A/ARF 2278
cDNA array 1193
cDNA microarray 929
cell adhesion 366, 2010
cell culture 2166
cell cycle 7
cellular localisation 1702
cellular retinoic acid binding protein 696
central nervous system 747
centrosome aberrations 389
cervical cancer 41, 1800
cervical neoplasias 601, 1794
cervix carcinoma 449
cetuximab 1063
CHEK2 784
chemoembolisation 1862
chemoendocrine treatment 467
chemoprevention 513
chemoprophylaxis 867
chemoprotection 294
chemoradiation 284, 1372
chemoradiotheraphy 1341
chemoradiotherapy 655, 1221
chemotherapeutic agents 1430
chemotherapy 36, 294, 334, 350, 459, 475, 673, 799, 1372, 1644, 1650
chemotherapy response 147
childhood 2042
children 2084
chimeric antibody 1069
CHK2 784
cholecystectomy 1307
cholesterol 1785
chromatin 1165
chromosome 382
chronic B-cell lymphocytic leukaemia (B-CLL) 1517
chronic pain 225
chronopharmacology 1684
cII gene 873
circulating tumour cells 906
circulating tumour DNA 2181
cisplatin 246, 334, 475, 639, 827, 1084, 1149, 1352, 1611, 1636, 1684
c-kit 1398
classic Kaposi’s sarcoma 188
classification 847
clinical trial 15, 1358
coactivator 2286
co-expression 1906
cohort 176, 2070
cohort studies 182, 194, 580, 995, 1302, 1326, 1803, 2042
colon 736, 1078, 1310
colon cancer 722, 985, 1307, 1655, 1803, 1846, 2240
colorectal 60, 426
colorectal adenoma 1193
colorectal cancer 24, 430, 651, 832, 838, 1055, 1137, 1746, 1782, 1842, 2233
colorectal cancer and antiangiogenesis 350
colorectal metastases 729
colorectal neoplasms 259, 434
combination 1006
combination therapy 722
comet 1626
comfrey 873
communication 1671
comparative genomic hybridisation 935
complement 895
condom use 1388
conformal radiotherapy 488
corticosteroid 867
cost 60
Cox-2 2225
CPT-11 882, 1055
C-reactive protein 21, 625, 651
Crohn’s like reaction 1746
CTL 72
curative resection 21
cutaneous squamous cell carcinoma 1326
CXCR4 503
cyclin D1 1581
Cyclin L1 770
CYFRA 21 13
CYP26 696
cytokines 921, 1450
cytomegalovirus 747
cytotoxic potential 1702
cytotoxic T cells 1450
Danish cancer patients 995
Danish cancer register 995
DCIS 162, 389
DDS 1240
death from all causes 2089
delay 1959, 1971
dendritic cells 1182
denial 1393
depression 1393
deprivation 1279
desmosome 2153
detection rates 597
dexamethasone 1084
DGGE 1144
diagnosis 236, 1959, 1971
diet 971
dietary fibre 1803
diethylstilbestrol 1538
differential expression 2249
differentiation 751
discordant sites 1288
disease associations 1298
disparities 1842
distress 990
diuretics 1302
DLK1 1574
DNA damage 334, 1524, 1626
DNA damage response 784
DNA double-strand break repair 1089
DNA methylation 838, 1165
DNMT3L 1934
docetaxel 15, 645, 827, 2129
dose escalation 488
dose intensity 832, 1019
dose optimisation 1055
dosimetry 298
drug combinations 1063
drug development 1837
drug interaction 681
drug resistance 80, 334, 1084, 1149
ductal carcinoma in situ 1720
E6 290
E7 290
early invasive colorectal carcinoma 1193
Ebp1 140
E-cadherin 985, 2018
ECF 1650
ECOG-ps 1834
ecological studies 1279
ECTO-NOX 690
efficacy 1855
EGF receptor 366
EGFR 1069, 1737, 1846
EGFR mutation 1922
EGFRvIII 1069
elastase 89
ELF 2122
endocrine tumours 94
endometrial cancer 2059
endometrium 1098
endostatin 89, 729
endothelium 503, 1493
endothelin A receptor 2148
energy balance 673
England 194
Ep-CAM 342, 882, 1767
epidemiology 1276, 1302, 1326, 1782, 1785, 1803
epidermal growth factor 1690
epidermal growth factor receptor (EGFR) 334, 1063, 1110, 1341, 1877, 2266
epidermal growth factor receptor(EGFR) gene 1711
epigenetics 1165
epirubicin 1989
epothilone B 1006
EPR effect 1240
Epstein–Barr virus 1593
ER 147
ER α 2286
ER β 2286
ErbB receptors 140
ErbB2 1421
ERK1 2206
ERK2 2206
ethnic differences 1787
ethnicity 1393
etoposide 639, 1019, 1486
Ewing tumours 705
exosomes 305
expression 376
extra-nasal 1226
Eysenck personality questionnaire-revised 2089
EZH2 1754
familial breast cancer 784
familial thyroid carcinoma 1892
family 1321
fast recruitment 1679
fat 971
fatty acid 971
FELV 1650
fever therapy 421
FGFR3 320
FGFR4 320
fibroblast growth factor 2, 705
first-line chemotherapy 246
FISH 770, 1253
flat penile lesions 1388
fluorescence in situ hybridisation 382
FNAB 389
folate 838, 1524
followup 430
follow-up study 1276
food frequency questionnaire 971
fried foods 2065
fruit 1782, 2059
γ-irradiation 320
G-17 1581
galectin-1 1188
gamma-glutamyl transpeptidase 294
garlic 1773
gastric 2122
gastric cancer 1051, 1130, 1273, 1759, 1767, 2190
gastric carcinoma 1850
gastric MALT lymphoma 312
gastrin 1506
gastrointestinal tumour 1117
gefitinib 13, 1110, 1690, 1711, 1846
gelonin 2004
gemcitabine 445, 645, 815, 1084, 1352, 1684, 2139
gene delivery 1414
gene expression 1553, 1934, 2240
gene expression profiles 1130
gene expression profiling 1506, 1561, 1915
gene–environment interaction 2039
genetic 60
genetic susceptibility 967
genistein 80
genotype 838
geographic 1842
German population 1159
germline mutations 1144, 2278
germline variation 784
Glasgow osteosarcoma 1684
GLC4 1459
glioblastoma 1247
glioma 747
glucocorticoids 876
GM-CSF 1019
Golestan 176
GPS 1834
grade 613, 625
Great Britain 587
Greece 396
GRIM-19 1892
groin nodes 222
growth factors 921, 1247, 1467, 1506, 1720, 1899
GRP 522
GTL2 1574
guidelines 867
H2AX 1089
haemoglobin beta (HBB) 2216
hair 1837
Hash-1 751
HB-EGF 1737
hDAB2IP 1117
head and neck cancers 539, 913, 1046, 1341, 1819
head and neck squamous cell carcinoma 770
heat shock protein 499
Helicobacter pylori 1273, 1759
Helicobacter pylori eradication 312
hepatitis-B virus 607, 935
hepatitis-C virus 607, 935
hepatocarcinogenesis 935
hepatocellular carcinoma 252, 628, 929, 935, 1690, 1754, 1825
hepatocyte growth factor 1506
HER-2 1261, 1421
HER-2/neu 72, 147, 1253
hereditary non-polyposis colorectal cancer (HNPCC) 1746
Hes-1 751
HGF 1078
HIF 94
high-dose 5-FU and leucovorin 1013
high-dose methotrexate 480
high-dose therapy 47
histology 847
histone acetylation 1117
histopathology 1366
HIV 194
HLA 1253
HLA-related genes 967
hMLH1 396
hMSH2 396, 2286
HNPCC 396, 2240, 2286
homeobox gene 2233
homocysteine 838
hormone replacement therapy 1293
hormone resistant 36
hormone therapy 2049
HOXB13 376, 2233
HPV 290
HPV type concordance 1388
H-Ras 80
hTERT 1942
hTR 1942
human papillomavirus (HPV) 265, 601, 891, 990, 1794, 1800, 2195
human prostate cancer 2018
Hürthle cell tumours 1892
hWAPL 290
hypericin 1406
hypoxia 94, 350, 655, 1696
IBDQ 1663
ifosfamide 1626
IGF-1 2097
IGF1 genotype 857
IGF-1 levels 857
IGF-1 receptor 2097
IGFBP-3 1283
IGFBP-6 1538
IGF-I 1467
IGF-II 1283
IGF-II IGF-IR 1467
ILF 2122
image cytometry 389
imaging 1046
imatinib 1398
imatinib mesylate 1881
ImiDs 217
immune responses 1358
immunoglobulin heavy chain gene 312
immunohistochemistry 113, 278, 743, 747, 1231, 1253, 1720, 1767, 2201
immunostaining 942
immunosurveillance 895
immunotherapy 799, 843, 895, 1069, 1253, 1450
imprinting 1574
in situ breast cancer 162
in situ hybridisation 743, 747, 2024
in vivo microscopy 729
incidence 188
India 601
inducible gene expression 681
inflammation 1268, 1927
informed consent 1001
inherited predisposition 2278
inherited predisposition to breast cancer 1144
inhibitor of apoptosis 120
in-house cDNA microarray 1915
inoperable pulmonary malignancy 1825
insulin-like growth-factor-I (IGF-I) 1283
insulin-treated diabetes 2070
integration 2195
integrin 1475
integrin β1 102
intensity-modulated radiation therapy 1819
interaction 1006
interferon 1655
interleukin 921
interleukin-12 1450
intestinal injury 294
intracellular signalling 539
intratumoral infusion 1414
intravesical therapy 2145
invasion 102, 1955
invasive breast cancer 162
invasive cervical cancer 891
invasive ductal carcinoma 847
Iran 176
Iressa 1063
irinotecan 15, 259, 722, 820, 1055, 1846, 1850, 2122
irradiation 539
Italy 188, 572
Japanese 2089
Japanese women 2102
K562 1486
Kaposi’s sarcoma 572, 1467
Ki-67 147
kidney neoplasms 2266
Ki-ras 405
Korean 1273
KP372-1 1899
K-ras 1098
large phase III clinical trials 1679
large-core needle biopsy 231
larynx 2185
LCIS 162
LENT SOMA 1663
leucovorin 24
leukaemia 1298, 2084
levamisole 1655
LHRH receptor 366
limited resection 1033
linkage 194
lipolysis 876
lipopeptide 1421
lipoproteins 1406
liposomes 1421
liver cancer 572, 1307
liver metastases 1825
liver neoplasms 607
liver transplantation 1862
LKB1 1126
localised cancer 236
LOH 236
longitudinal 673
longitudinal study 1834
long-term 1800
loss of heterozygosity (LOH) 30, 1517
low-dose radiotherapy 1221
LPAAT-β 1729
luminescence 298
lung cancer 131, 580, 743, 942, 1033, 1084, 1089, 1231
lung neoplasms 1321
lymph nodes 156
lymphadenectomy 1051
lymphangiogenesis 1720
lymphatic metastasis/pathology 2201
lymphocyte infiltration 1746
lymphoma 1298, 1352, 1593
M30-Apoptosenseâ„¢ Elisa 532
magnetic resonance 1599
malignancy 570, 867
malignant lymphoma 1349
malignant melanoma 201
mammaglobin 1948
mammographic screening 1366
mammography 156, 597, 949, 955, 961, 2102
management 459
MAPK pathway 2032
maspin 1130, 1948
mastectomy 55, 225
maternal hormone levels 1787
mathematical model 47
matrix metalloproteinases 252, 2171
MC-26 cells 1581
MCP-1 2024
MDM2 2097
meat 1310
medulloblastoma 359
melanoma 662, 1398, 1499, 2249
membrane vesicles 305
menstruation 1098
mesna 1636
mesothelioma 580, 587
messenger ribonucleic acid 259
MET 1078, 1906
meta-analysis 131, 430, 434, 935, 1033, 2049, 2076
metastases 1690
metastasis 449, 503
metastatic 673, 2122
metastatic breast cancer 475, 1989
metastatic disease 634
metastatic oesophageal cancer 2129
metastatic pancreatic cancer 2139
metastatic survival 1382
methotrexate 24
methotrexate toxicity 480
methylation 760, 942, 1117, 1486, 1574
methylation specific PCR 1117
mice 1684
microarray profiling gene expression pattern 80
microarrays 376, 618, 1149, 1545
micrometastases 222, 906
micrometastasis 1948
microsatellite instability (MSI) 1517, 1746, 2240
mismatch repair 1137
mitochondria 513, 1459
mitochondrial DNA 1268
mitochondrial proteins 1892
mitogen-activated protein kinases 2266
mitogenic signalling 921
mitosis 1773
mixture 2160
MLPA 396
MO25α 1126
molecular targeted agents 799
molecular therapy 1899
monoclonal antibodies 1442
mortality 241, 426, 587, 955
motility 1955
MS 838
MT201 342
MTHFR 838
mucinous adenocarcinoma 259
multiphoton laser scanning microscopy 729
mutation 30, 1711, 2032, 2160
MX2 1486
myeloma 217
myocardial infarction 1614
nasopharyngeal cancer 967
nasopharyngeal carcinoma 799, 1382
natural history 156
natural killer cell lymphoma 1226
natural resistance 1711
neoadjuvant chemoradiotherapy 1215
neoadjuvant chemotherapy 147
neoplasms 421, 570
neovascularisation 553
nested case–control study 1273
neural system tumours 2278
neuroblastoma 751, 1984
neuroendocrine tumours 1506
neuropilin-1 328
neurotoxicity 832
NF-κB 711, 1137, 1593
NK105 1240
nonmelanocytic skin cancer 201
nonseminoma 1934
non-small-cell lung 15
non-small-cell lung cancer 13, 459, 1038, 1834
Notch 751
Nottingham Prognostic Index 847
novel treatments 217
NSAIDs 1137
NSCLC 775
NSCLC cells 681
nuclear and cytoplasmic staining 113
occupation 1276
Octreotide 1493
oesophageal cancer 176, 284
oesophageal neoplasms 2065
oestradiol 547
old age 1221
older women 1794
oleate 971
olfaction 1611
oligonucleotide array 2249
oligonucleotide microarray 1130
oncogenes 770, 2190
oncogenic viruses 743
oncology 421
ongoing mutation 312
oral chemotherapy 1989
oral neoplasms 2065
oral squamous cell carcinoma 30, 2181
oral vinorelbine 1989
organ metastasis 1746
osteoclast 1531
osteosarcoma 1358
ovarian 60
ovarian adenocarcinoma 2024
ovarian cancer 113, 271, 278, 305, 1026, 1149, 1475, 1729, 1737, 1927
ovarian neoplasm 895
ovarian surface epithelium 1927
overweight 2042
oxaliplatin 259, 655, 832, 1644
oxidative stress 1696
p21 131, 284
p53 30, 284, 1089, 1137, 2097
P53 gene 434, 1144
p53 status 2114
p53R2 284
paclitaxel 320, 634, 639, 1240
paediatric 1626
palliative treatment 1038
pancreas 94, 1372
pancreatic cancer 21, 89, 405, 445, 921, 971, 1307, 2076
pancreatic carcinoma 2225
papillary 1545
papillary thyroid cancer 2216
Parkinson’s disease 201
parotid gland 539
patient 1959
patient motivations 1001
patients’ preferences 807
PDGF-R 1398
pegylated liposomal doxorubicin 628
PEI 1862
pelvic radiotheraphy 1663
peptide 328
perfusion 1406
peritoneal fluid 1737
permeability 1406
peroxisome proliferator-activated receptor 113
Peutz–Jeghers syndrome 1126
PgR 147
pharmacodynamic 1837
pharmacogenomics 259
pharmacokinetics 820, 1006, 1636, 1855, 2004
pharyngeal neoplasms 2065
phase I 820, 1636
phase I study 815, 2139
phase II 15, 445, 628
phase I/II cancer clinical trials 1001
phase III trial 488
phosphatidic acid 1729
phosphorylation 2206
photochemical internalisation 2004
photodynamic therapeutic agent 1702
photodynamic therapy 298, 1406, 1442, 2004
PI3-Akt 681
picropodophyllin 1467
plakoglobin 2153
plasminogen activation 1475
platinum pretreatment 1019
PNA 405
Pneumocystis pneumonia 867
polycomb group protein 1754
polymer micelles 1240
polymorphisms 30, 2039, 2262
pooled analysis 1288
population-based 182, 995
population-based study 1293
population-based survival 1808
positron emission tomography 655
post mastectomy pain 225
post-Chernobyl 1545
post-operative 1372
precounselling needs 1671
prediction 434, 587, 613
prediction response 618
predictive marker 2114
predictivity 1261
pregnancies 167
pre-hospital 1971
premenopausal 467
premenopausal breast cancer 857
prescriptions 594
primary care 1959
proband 1321
prognosis 271, 278, 434, 449, 576, 618, 847, 1026, 1231, 1906, 1955, 2181, 2206, 2225
prognostic factors 13, 131, 662, 1382, 1767
programmed cell death 120
progression 2018
proliferation 751, 1467, 1493, 1506, 1881
promoter hypermethylation 775, 2190
prospective cohort study 857, 2089
prospective study 1283, 1782
prostate 376, 426, 503, 2166
prostate cancer 36, 140, 320, 366, 488, 1159, 1538, 1819, 2171
prostrate cancer 499
proteasome inhibitors 217
proteasome proteolysis 711
protein biosynthesis 2266
protein degradation 711
protein tyrosine kinases 1906
proteolysis-inducing factor (PIF) 711
PSA 488
PTEN 1711
pTNM 847
public understanding 265
pyrrolizidine alkaloid 873
quality of life 668, 990, 1869
quantitative RT-PCR 532
quercetin 499
R116010 696
Rab1a gene 1915
race 2084
Rad51 1089
radiation 125
radiation therapy 1614
radiation toxicity 488
radical radiotherapy 41
radiofrequency 1825
radioresistance 2185
radiosensitisation 125, 815
radiotherapy 449, 459, 799, 1038, 1201, 1372, 2114
raltitrexed 445
Raman spectroscopy 2166
randomisation 807
randomised controlled trials 811
RAS 131, 2032
RAW 264.7 1531
reactive oxygen species 1759
real-time PCR 405, 547, 775, 2249
rearrangements 396
receptors 1720
receptor specificity 2148
record linkage 1298, 1307
rectal cancer 655, 1209, 1215, 2114
rectal carcinoma 1209
rectum 1310
recurrences 430, 1026
redox state 690
referral 1959, 1971
refractory 1352
regulatory T cells (Treg) 913
relapsed 1352
remnant stomach cancer 562
renal cell cancer incidence 1302
renal cell carcinoma 843, 1421, 1825, 2010
renal development 2010
renal transplant 572
replication errors positive phenotype (RER+) 1517
research 613
research spending 241
resection 1372
resveratrol 513
retinoic acid 696
risk 594, 1302, 1349
risk factors 1273, 2042, 2065
RNASEL 1159
RON 1906
RUNX3 562
rye 1803
S-1 2139
safety 1855
saline hydration 1636
salvage chemotherapy 1850
salvage surgery 430
salvage therapy 1019
sarcoma 2004
SCID mice 72
SCLC 522
screening 55, 156, 597, 949, 955, 1800
screening frequency 961
screening interval 961
second primary 570
secondary care 1959, 1971
secondary cytoreductive surgery 1026
second-line chemotherapy 15
segmentectomy 1033
selective chemotherapy 499
seminoma 1934
semiquantitative PCR 278
sentinel lymph node biopsy (SLNB) 662
sentinel lymph node biopsy/methods 2201
sequential hemi-body irradiation 1984
sequential hormonal therapy 1621
serine proteases 760, 2171
serological analysis of recombinant cDNA expression libraries 929
serous papillary uterine cancer 1561
serum biomarker 2018
serum DNA 2181
sex hormone 1877
sFGFR 320
shortening 668
short-term preoperative radiotherapy 1209
signalling 2153
signalling pathways 1690
singlet oxygen 298
siRNA 290
skeletal metastases 1869
skin 570
skin cancer 499
small-area geography 1279
small-cell lung carcinoma 1553
small-molecule therapy 1922
smear test 990
smell 1611
smoking 426, 1321
smoking tobacco 1326
smoky coal exposure 1321
SNAIL 252, 985
snuff dipping 1326
social deprivation 631
sociodemographic 1971
socioeconomic status 1279
solid tumours 1855
soluble vascular endothelial growth factor receptor-1 553
SOM230 1493
somatostatin receptors 1493
SPARC 942
SP-D 522
SP-G 522
spheroid 882
splicing variants 1942
spontaneous neoplasm regression 421
squamous cell 570
squamous cell carcinoma (HNSCC) 1046, 1341
SSCP 2024
SSI 389
ST14 278
stage 625
stage I non-seminoma 2107
Stat1 1149
statin 1593
statistical methods 576
stearate 971
stem cell 2160
stomach cancer 1307
stomach neoplasms 827
STRADα 1126
subsequent malignancy 1288
suicide 995
surgery 459, 1209
surgical decision-making 631
surrogate 955
survival 21, 131, 459, 625, 651, 1279, 1329, 1767, 1834, 2089
survival analysis 576
survival signals 705
survivin 212, 271, 359
Survivin isoforms 359
survivin-2B 212
survivin-DEx3 212
surviving 2225
susceptibility 784
systematic review 131, 434
T lymphocytes 305
TADG-15 278
tamoxifen 547, 1098, 1614
tandem base substitution 873
targeted agent 1855
targeted therapy 7
targeted treatment 217
taxonomy 613
TCF4 2233
telomerase 1881, 1942
testicular cancer 1934
testicular germ cell cancer 1787
testicular neoplasm 1785
Testisin 760
TFPI-2 775
thalidomide 217
therapeutic trials 1599
therapy 985
thermal ablation 1825
thioredoxin 350
thromboembolism 1349
thymidine phosphorylase 1696
thyroid 1545
thyroid cancer 1892
time since births 167
tissue microarray analysis 770
tissue microarrays 743
tongue squamous cell carcinoma 1915
topoisomerase 1486
toremifene 1098
toxicity 1663
TRAIL 736, 1430
TRAIL receptor 1 1430
transactivation 2286
transformation 522, 1078
transgenic rat 873
transitional cell carcinoma 645, 2262
translocation 382
trastuzumab 342, 1261
treatment 1226
trends 1201
trial 949
trial registration 811
TSA 751
tumorigenesis 212, 1268
tumoritropic behaviour 1406
tumour 421
tumour antigens 929
tumour lysates 72
tumour necrosis factor alpha 1690
tumour progression 366, 2249
tumour size 21
tumour suppressor 760
tumour suppressor genes 2190, 2216
tumour-associated NADH oxidase 690
tumour-immune escape 1188
turkmen 176
type 2195
type-II diabetes 2076
tyrosine kinase 1922
tyrosine kinase inhibitor 1877
tyrphostins 294
UFT 827
Uganda 1808
UK Europe 1329
ultrasound 231, 499
undescended testes 1787
undifferentiated thyroid cancer 1110
United Kingdom 1794
untreated phase III 1650
urban–rural differences 2084
urokinase plasminogen activator receptor 1475
uveal melanoma 2032
Vaizey 1663
validation 668
variation 55
vascular endothelial growth factor 553
vascular endothelial growth factor A 1182
vascular endothelial growth factor receptor-2 553
vascular invasion 1754
vasopressin 522
VDR 985
vegetables 1782, 2059
VEGF 328, 1467, 1531, 1696
VEGFR1 1531
VEGFR2 1531
vinorelbine 634
viral hepatitis 1268
viral load 891, 2195
virus dissemination 1414
vitamin D 985
volunteer studies 2148
VPA 751
vulval cancer 222
vulval squamous cell carcinoma 102
waiting times 1201
wedge resection 1033
weekly vinorelbine 1013
Western blot analysis 532
whole grains 1803
wild-type K-ras 1310
xenografts 722
Xeroderma Pigmentosum Group C (XPC) 2262
XIAP 532
XR5944 722
years of life lost 241
ZD1839 13, 125
ZD 4054 2148
zinc-α2-glycoprotein 876
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keyword Index for Volume 92. Br J Cancer 92, 2302–2306 (2005). https://doi.org/10.1038/sj.bjc.6602670
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6602670